Details for Patent: 5,948,437

Scope, Claim Strength, and U.S. Patent Landscape for Drug U.S. Patent 5,948,437

What is covered by U.S. Patent 5,948,437?

U.S. Patent 5,948,437 claims a sustained-release formulation built around a specific active ingredient and a specific class of gelling agents (hydroxypropyl methylcellulose, “HPMC”), plus defined excipient options and process routes.

At the highest level, the claim set has three coverage layers:

1. Composition: sustained-release formulation comprising the drug candidate plus gelling agent plus excipients (independent claim).
2. Gelling agent narrowing: HPMC type selection and viscosity/methoxy/hydroxypropoxy constraints (dependent claims).
3. Downstream use and manufacture: treating psychotic states or hyperactivity; and specific tablet preparation workflow.

What is the core independent claim and its scope? (Claim 1)

Claim 1 is the foundational breadth anchor:

• Product: “A sustained release formulation comprising a gelling agent and [the active] … together with one or more pharmaceutically acceptable excipients.”

Active ingredient identity (as recited)
“11 - 4- 2-(2-hydroxyethoxy)ethyl!- 1 -piperazinyl!dibenzo- b,f! 1,4!thiazepine or a pharmaceutically acceptable salt thereof.”

Gelling agent (open category in Claim 1)
Claim 1 does not limit the gelling agent to HPMC. It is framed as “a gelling agent,” leaving room for other gelling agents unless limited by dependent claims or prosecution history.

Excipients
Claim 1 also uses open language: “one or more pharmaceutically acceptable excipients.”

Practical interpretation for infringement scope
A product literal to Claim 1 must include:

• The exact listed drug (or a pharmaceutically acceptable salt), and
• A sustained-release formulation, and
• A “gelling agent,” and
• At least one pharmaceutically acceptable excipient.

The main litigation leverage in Claim 1 is the identity of the active and the sustained-release + gelling agent functional relationship, which can be attacked through formulation characterization arguments (whether something qualifies as “sustained release” or as a “gelling agent”), but Claim 1 is otherwise structurally simple.

How does the patent narrow scope via HPMC definitions? (Claims 2–7)

Claim 2: HPMC only

Claim 2 limits the gelling agent to:

• Hydroxypropyl methylcellulose (HPMC)

This is a key narrowing point. If a competitor uses a different gelling agent (e.g., sodium alginate, carbomer, ethylcellulose, polymethacrylates, PEO-based matrices), it can avoid the dependent claim family, but still risks Claim 1 if the alternate gelling agent qualifies as “a gelling agent” in Claim 1.

Claim 3: weight % range + HPMC grade list with compositional constraints

Claim 3 adds two major limitations:

1. HPMC amount: “about 5 to 50% by weight” of a selected HPMC from a defined group (a)–(d)
2. HPMC grade selection: HPMC is restricted by:
   • viscosity (cps range),
   • methoxy content (wt%),
   • hydroxypropoxy content (wt%).

It also adds a proviso that affects grade combinations:

• If the formulation contains HPMC under (d) (viscosity about 3,500 to 5,600 cps; methoxy about 19 to 24%; hydroxypropoxy about 7 to 12%), then the total HPMC amount must be greater than 25.8% by weight.

Claim 3 grade group (verbatim parameterization)

• (a) viscosity about 40–60 cps, methoxy 28–30%, hydroxypropoxy 7 to <9%
• (b) viscosity about 3,500–5,600 cps, methoxy 28–30%, hydroxypropoxy 7–12%
• (c) viscosity about 80–120 cps, methoxy 19–24%, hydroxypropoxy 7 to <9%
• (d) viscosity about 3,500–5,600 cps, methoxy 19–24%, hydroxypropoxy 7–12%

Claims 4–7: successive HPMC loading narrowing

These are incremental narrower ranges, each stacking on top of Claim 3’s grade constraints.

• Claim 4: about 5 to 40% HPMC (from (a)–(d) or mixtures)
• Claim 5: about 8 to 35% HPMC
• Claim 6: about 10 to 30% HPMC
• Claim 7: about 15 to 30% HPMC

Scope consequence
Claim 2 establishes the gelling agent must be HPMC. Claims 3–7 then define:

• which HPMC grades qualify, and
• how much HPMC can be used, with tighter ranges as you go deeper into the dependent chain.

For practical freedom-to-operate, the key question is not just “HPMC used,” but whether the HPMC grade falls inside the parameter rectangle and whether the wt% lands inside the dependent loading band (including the Claim 3 proviso condition for grade (d)).

How are excipients limited? (Claims 8–9)

Claim 8: excipient option set

Claim 8 restricts excipients to a defined group:

• microcrystalline cellulose
• lactose
• magnesium stearate
• sodium citrate
• povidone

Claim 9: excipient quantitative ranges

Claim 9 further defines ranges:

• microcrystalline cellulose: about 4 to 20%
• lactose: about 5 to 20%
• magnesium stearate: about 1 to 3%
• sodium citrate: about 10 to 30%
• povidone: about 1 to 15%

This claim structure is a classic “tight formulation” dependency: a competitor using the same active and sustained-release HPMC system but adding different excipients or using out-of-range excipient levels can avoid dependent claim capture, while still potentially running risk under broader Claim 1 (depending on whether the excipient limitation is interpreted as required only for the dependent claims).

What salt form coverage exists? (Claim 10)

Claim 10 adds a salt-specific narrowing:

• the active is in the form of a hemifumarate salt.

This does not narrow Claim 1, which is “active or pharmaceutically acceptable salt.” But it provides an extra hook: formulations using the exact hemifumarate salt are captured by Claim 10’s dependent layer.

For infringement analysis, hemifumarate usage increases claimant leverage because it removes one possible design-around axis (switching salt form).

What pH modifier limitation exists? (Claims 11–12)

• Claim 11: one excipient is a pH modifier
• Claim 12: the pH modifier is sodium citrate

This matters because sodium citrate is already part of the excipient set in Claim 8 and its quantitative band in Claim 9. Claim 12 is an additional explicit constraint: even if a formulation uses the other excipients, swapping the pH modifier away from sodium citrate could help avoid Claim 12 while staying inside Claim 9 only if sodium citrate remains within the Claim 9 range (which Claim 9 explicitly includes as an option with a range).

What therapeutic method claims are included? (Claim 13)

Claim 13 is a method-of-treatment claim:

• “treating psychotic states or hyperactivity”
• in “warm-blooded animal”
• by administering an “effective amount” of the formulation of Claims 1–12.

This provides a second infringement theory:

• even if a formulation is disputed as a “sustained release” composition under product claims, the method claim can still be asserted if the administered product falls within the covered formulation scope.

It also broadens potential plaintiffs: clinics and prescribers are implicated in method enforcement, though in practice enforcement risk depends heavily on regulatory labeling and proof of “effective amount” administration.

What process claims exist for tablet manufacturing? (Claims 14–15)

Claim 14: generic mixing

Claim 14 covers:

• mixing the active (or salt), a gelling agent, and other excipients
• to prepare the formulation of Claims 1 or 2.

This is broad but operationally relevant. It captures manufacturing steps even if the final tablet composition is debated, as long as the process is used to make the claimed sustained-release formulation.

Claim 15: specific wet granulation tablet workflow

Claim 15 adds an explicit step sequence: (a) mix active (or salt), gelling agent, and other excipients
(b) wet granulating
(c) drying
(d) milling
(e) blending with lubricant
(f) compressing to form tablets

This is narrower than Claim 14 and is most helpful against competitors who follow the same tablet manufacturing route.

What does the claim architecture mean for competitive design-around?

The patent is built around an enforceable “core” plus multiple narrowing layers.

Design-around axes

1. Active ingredient substitution
   Avoiding the exact active (or its pharmaceutically acceptable salt) is the cleanest avoidance. The claims do not appear to cover analogs with different core structures.

2. Salt form choice
   Hemifumarate is only claimed in Claim 10. Avoiding hemifumarate can reduce dependent coverage but not necessarily Claim 1 if “pharmaceutically acceptable salt” still includes your chosen salt.

3. Gelling agent switch

   • Switching away from HPMC helps avoid Claims 2–7 and may avoid some dependent formulations.
   • Switching to an alternate gelling agent does not automatically avoid Claim 1 because Claim 1 still requires “a gelling agent” generally.

4. HPMC grade and parameter matching Even when HPMC is used, Claims 3–7 require parameter-defined HPMC grades (viscosity, methoxy content, hydroxypropoxy content) and define wt% bands.

5. Excipient system Claim 8 and Claim 9 define both identities and quantitative ranges. Changing excipients or levels can avoid those dependent claims.

6. pH modifier Sodium citrate is explicitly recited in Claim 12. Avoiding sodium citrate as the pH modifier can reduce Claim 12 exposure.

7. Manufacturing route Claim 15 requires wet granulating through tablet compression workflow. Altering to direct compression or different granulation/drying/milling steps can avoid Claim 15 while still risking Claim 14 or composition claims.

Claim-by-Claim coverage map (infringement risk lens)

U.S. Patent 5,948,437 landscape: what else matters for freedom-to-operate?

Primary landscape driver inside this patent

This patent’s enforceable core is not “any sustained-release of this drug,” but a specific sustained-release formulation architecture:

• the active (or salt),
• a gelling agent (HPMC in dependent layers),
• with parameter-defined HPMC grades and specific excipient limitations (in deeper dependents),
• plus a manufacturing workflow (wet granulation tablet process in Claim 15).

That structure means landscape risk is highly formulation-specific.

Key competitor decision points

• Do they use HPMC? If yes, which HPMC grade (viscosity/methoxy/hydroxypropoxy) and at what wt%?
• Do they use sodium citrate? If yes, is it a pH modifier and in what amount?
• Do they use microcrystalline cellulose, lactose, magnesium stearate, povidone within the specified bands?
• Do they manufacture by wet granulation then compress tablets? If not, they can reduce risk under Claim 15 (but not necessarily under composition claims).

Scope summary in one page

• Independent claim (1) covers: sustained-release formulation with the specified active (or a pharmaceutically acceptable salt), a gelling agent, and excipients.
• Dependent claim chain (2–7) locks to HPMC gelling agent and imposes both:
  • HPMC content ranges (progressively narrowing), and
  • HPMC grade constraints based on viscosity, methoxy content, and hydroxypropoxy content, plus a proviso for grade (d).
• Dependent claim chain (8–12) locks the excipient set and ranges, with sodium citrate singled out as the pH modifier.
• Method claim (13) covers administration to treat psychotic states or hyperactivity.
• Process claims (14–15) cover mixing generally and a specific wet granulation tablet production route.

Key Takeaways

• U.S. Patent 5,948,437 is strongest against formulation copycats that use the claimed active (or salt), sustained-release structure, and especially HPMC grades defined by viscosity/methoxy/hydroxypropoxy parameters at specified wt% levels.
• The patent contains layered narrowing: even if a product avoids the deepest HPMC grade constraints, Claim 1 still focuses on a “gelling agent” sustained-release formulation with the same active.
• Dependent excipient constraints and the sodium citrate pH modifier hook create additional design-around friction, especially for tablet formulations in standard excipient sets.
• Process risk concentrates in wet granulation tablet routes (Claim 15) but compositional scope remains the primary exposure.

FAQs

1. Does Claim 1 require HPMC specifically?
   No. Claim 1 requires “a gelling agent.” HPMC is required in Claim 2 and above.

2. What is the most formulation-sensitive element?
   The HPMC grade constraints in Claim 3 (viscosity, methoxy, hydroxypropoxy) combined with the HPMC wt% ranges (Claims 3–7), including the proviso tied to HPMC grade (d).

3. Can switching from hemifumarate avoid the patent?
   It can avoid Claim 10 specifically, but it does not avoid Claim 1 unless the new salt falls outside “pharmaceutically acceptable salt” and avoids all dependent layers tied to excipients and HPMC grades.

4. Do excipient changes fully remove risk?
   They can avoid dependent claims (Claims 8–12), but Claim 1 still requires “one or more pharmaceutically acceptable excipients” without restricting identities.

5. Does Claim 15 matter if a product uses a different manufacturing route?
   It reduces risk under Claim 15’s specific wet granulation workflow, but Claim 14 (mixing-based process) and all composition claims still apply if the product is covered.

References

[1] U.S. Patent 5,948,437.